Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236080 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT00236080 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 136 participants.
The verdict
NCT00236080, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).
Interventions
- DRUG Placebo
- DRUG PROVIGIL 200 mg
- DRUG Armodafinil 250 mg
- DRUG Armodafinil 200 mg
- DRUG Armodafinil 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2005-08 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236080
The ClinicalTrials.gov registry entry for NCT00236080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00236080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00236080 about?
NCT00236080 is a clinical study titled "Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL". The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).
What is the current status of trial NCT00236080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2005-08. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00236080?
The interventions under investigation include: Placebo (DRUG), PROVIGIL 200 mg (DRUG), Armodafinil 250 mg (DRUG), Armodafinil 200 mg (DRUG), Armodafinil 150 mg (DRUG).
Who is sponsoring clinical trial NCT00236080?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.